Anito-cel for Multiple Myeloma

This NEJM item (Volume 395, Issue 12, pages 1233-1236) addresses anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. As a short correspondence or editorial-length piece rather than a full trial report, it discusses the efficacy and safety profile of a third CAR T product entering a field already served by idecabtagene vicleucel and ciltacabtagene autoleucel. The clinical relevance lies in expanding BCMA-targeted options for patients who have exhausted immunomodulatory drugs, proteasome inhibitors and anti-CD38 antibodies.